



Endorsed by
Paediatric Diseases
Working Party (PDWP)

Supported by

abu dhabi
Convention & Exhibition Bureau

3rd EMIRATES PEDIATRIC BONE MARROW TRANSPLANT & GENE THERAPY CONGRESS

"International get-together of Pediatric BMT physicians
to celebrate the success of saving children globally"

"Under the auspices of the Pediatric Diseases Working Party of
The European Blood and Marrow Transplantation (EBMT)"



9-10
November 2024



Grand Hyatt Hotel
Abu Dhabi, UAE

In association with



CONFERENCE BOOK

INDEX

Welcome Message	3
Learning Objectives Highlighted Topics & Key Features Why You Should Attend?	4
Organizing and Scientific Committee	5
International Advisory Board	8
Speakers	9
Session Chair	11
Scientific Program	13
General Informations & CME Accreditation	15
Speakers' Bio & Talk Overview	17
Poster Presenters	30
Sponsors & Exhibitors	35

WELCOME MESSAGE



Dr. Zainul Aabideen



Prof. Rupert Handgretinger

Dear friends and colleagues,

We are delighted to welcome you to the 3rd Emirates Pediatric Bone Marrow Transplant and Gene Therapy Congress, taking place on 9-10 November 2024 at the Grand Hyatt Hotel, Abu Dhabi, UAE. The EPBMTC is dedicated to advancing pediatric healthcare and enhancing patient outcomes by providing a platform for global professionals to come together, share knowledge, and collaborate on the latest advancements in pediatric bone marrow transplantation. This year's event features a comprehensive program, including keynote speeches from esteemed experts, poster and oral presentations, and engaging panel discussions.

The 2024 EPBMTC offers a rich scientific agenda, with a variety of educational sessions that address the current practices and challenges in Pediatric Hematopoietic Stem Cell Transplantation (HSCT) and Cell Therapy. With the UAE's commitment to establishing a premier Pediatric Bone Marrow Transplant Center, this congress will foster high-level scientific discussions and networking, significantly advancing Pediatric BMT practices in the region.

Additionally, the congress provides numerous opportunities for networking, allowing you to connect with like-minded professionals and cultivate collaborative relationships. We firmly believe that collaboration is essential for driving progress and achieving breakthroughs in our field.

Beyond the invaluable learning experiences, we invite you to immerse yourself in the vibrant ambiance of Abu Dhabi. Explore the city's rich culture, indulge in its culinary delights, and create lasting memories in this remarkable destination.

This gathering promises to uphold the highest standards of scientific and educational excellence while providing an ideal venue for networking with both national and international participants. We encourage you to seize this opportunity for growth, exchange ideas, and contribute to our collective pursuit of excellence. Together, we aim to elevate the standards and practices in pediatric bone marrow transplantation, and your active participation is vital to realizing this vision.

We warmly welcome each of you to the beautiful city of Abu Dhabi to celebrate our remarkable achievements and shape the future of pediatric bone marrow transplantation, making a lasting impact on the lives of young patients and inspiring one another toward future breakthroughs.

Thank you once again for your participation. We look forward to a successful and unforgettable experience.

Dr. Zainul Aabideen
CCT(UK), FRCPCH

Conference Chair
Chairman Organising & Scientific Committee
Consultant and Head of Pediatric Haematology,
Oncology & BMT,
Burjeel Medical City
Abu Dhabi, UAE

Prof. Dr. Rupert Handgretinger

Conference Co-Chair, Chairman Scientific committee
Prof. emeritus, Children's University Hospital, Germany
George and Jennifer Yeo Endowed Chair for
Pediatric Hematology, National University Singapore;
Consultant, Abu Dhabi Stem Cells Center (ADSCC)
and Yas Clinic Khalifa City (YCKC), Abu Dhabi, UAE

LEARNING OBJECTIVES

- Increase knowledge in bone marrow transplant in pediatrics.
- Deepen understanding of advanced topics in bone marrow transplant.
- Address the unmet need for greater understanding of and the screening for long-term complications in the growing population of survivors of transplantation for nonmalignant disorders
- Acquire new skills to apply learnings to practice
- Improve care of pediatric BMT patients
- Provide additional source of ongoing education for Advanced practice providers
- Provide the tools for a successful bone marrow transplant and immune effector cellular therapy in an educational setting.
- Offer an in-depth exposure to multidisciplinary approaches to hematological malignancies and multi-modal management strategies.
- Provide exposure and training in BMT/IEC
- Discuss updates in research in the field of hematologic malignancies, BMT, and/or cellular therapy.
- Allow the opportunity to improve medical knowledge, and overall subspecialty competence related to the areas of bone marrow transplant.

HIGHLIGHTED TOPICS

- BMT for Non-Malignant conditions such as Hemoglobinopathies, Primary Immune Deficiency, Inherited Bone Marrow Syndromes, and metabolic conditions.
- BMT for malignant conditions.
- Autologous BMT in children.
- Pre-transplantation workup.
- Management of complications during BMT.
- Supportive care in BMT.
- Infections during BMT, monitoring, prevention, and treatment.
- Stem cell manipulations in pediatric BMT.
- Late Effects after Pediatric Hematopoietic Cell Transplantation
- And many more

KEY FEATURES

- Full two-day program.
- Presentations by renowned expert speakers
- Interactive Sessions
- Connecting scientific community
- World class exhibits.

WHY YOU SHOULD ATTEND?

- Meeting renowned experts from around the world
- Networking and developing new partnerships
- Learning and sharing best practices
- Get introduced to success stories & achievements
- Learning novel concepts & practices in Pediatric Bone Marrow Transplant

WHO SHOULD ATTEND?

This activity is designed to meet the needs of:

- Pediatric oncologist.
- Pediatric hematologist.
- Pediatric BMT physicians.
- Pediatric infectious disease physician.
- Pediatric gastroenterologist.
- Pediatric other Subspecialists
- Pediatric Trainees
- Pediatric hematology, oncology, and BMT residents & Fellows.
- Stem cell lab professionals.
- Specialist Nurses
- Psycho-social counsellors.

ORGANIZING COMMITTEE



Dr. Zainul Aabideen

CCT(UK), FRCPCH, Conference Chair
Chairman Organizing committee
Consultant and Head of Pediatric Haematology,
Oncology & BMT,
Burjeel Medical City Abu Dhabi, UAE



Dr. Muhammad Faisal Khanani

Co -chair of organizing committee
Chief, Division of Pediatric Hematology
and Oncology, Consultant Pediatric Oncology
Tawam Hospital, Al Ain, UAE



Dr. Naser Al Zien

Head of Service and Consultant Pediatric
Hematology/Oncology, Mediclinic-Middle east
Adjunct Clinical Associate Professor of
Pediatric hematology/oncology
Mediclinic-Middle east, Mohammed Bin Rashid
University of Medicine and Health Sciences
(MBRU), Dubai, UAE



Dr. Mustafa Baroudi

Consultant Pediatric Oncologist Hematologist,
NMC Royal Hospital, Khalifa City,
Abu Dhabi, UAE



Dr. Deepthi Boddu

Specialist Pediatric Oncologist
Burjeel Speciality Hospital, Sharjah, UAE




Dr. Samina Afzal

Consultant Pediatric Hematology &
Oncologist, Sheikh Khalifa Medical City,
Abu Dhabi, UAE



Dr. Sagar Mohan Nivargi

Specialist - Department of Pediatric Hematology
Oncology & Bone Marrow Transplantation,
Burjeel Medical City, Abu Dhabi, UAE



Dr. Grace Nehme

Pediatric Hematologist Oncologist,
Clemenceau Medical Center,
Dubai, UAE



Dr. Haytham Al Jabour

Pediatric hematology,
Oncology and BMT Specialist,
Sheikh Khalifa Medical City,
Abu Dhabi, UAE



Dr. Hani Humad

Consultant Pediatrician
Pediatric Oncology/ Hematology Unit
Al Jalila Children's Hospital, Dubai, UAE



Dr. Nancy Israel

Specialist Pediatric Hematology Oncology
NMC Royal Hospital, Sharjah UAE



Dr. Philip Shabo

Senior Director of Operations- (BCI)
Burjeel Medical City
Abu Dhabi, UAE



Mr. Abdullah Odat

Pediatric Hematology / Oncology and
BMT Operational Manager ,
Burjeel Medical city
Abu Dhabi , UAE



Mr. Mohammed Alfar

Oncology pharmacy manager
Burjeel Medical City, Abu Dhabi, UAE



ORGANIZING COMMITTEE



Dr. Fatheya Abbas Al-khaja

Director of Dubai Thalassemia Center
Dubai Health
Dubai, UAE



Dr. Sakher Obeidat

Specialist Pediatric Hematology –
Oncology and BMT
Abu Dhabi Stem Cells Center(ADSCC)
Abu Dhabi, UAE



Randolina Radwan Mostafa Sirawan

Senior International Business
Development Manager
Abu Dhabi Stem Cells Center(ADSCC)
Abu Dhabi, UAE



Prof. Hanan Fawzy Nazir Abouelkhel

Professor of Pediatric Hematology,
Alexandria University, Consultant and
head of pediatric hematology unit,
Al Qassimi Women and Children Hospital
Sharjah, UAE



Mr. Mohammed Taher Abdal-Hamid Dar Yahya

Nurse Manager, Pediatric Hematology
and Oncology Services, Burjeel Medical City,
Abu Dhabi, UAE



Mr. Khalid Al Habaiba

Nurse Manager,
Pediatric Hematology-Oncology Unit,
Tawam Hospital, Al Ain, UAE



SCIENTIFIC COMMITTEE



Prof. Dr. Rupert Handgretinger

Conference Co-Chair, Chairman Scientific committee
Prof. emeritus, Children's University Hospital, Germany
George and Jennifer Yeo Endowed Chair for
Pediatric Hematology, National University Singapore;
Consultant, Abu Dhabi Stem Cells Center (ADSCC)
and Yas Clinic Khalifa City (YCKC), Abu Dhabi, UAE



Prof. Fouzia Nambiatheyil Aboobacker

Co-Chair of scientific committee
Professor of Hematology
Consultant Pediatric Hematology
Department of Hematology,
Burjeel Medical City, Abu Dhabi, UAE



Prof. Shahrukh Khurshid Hashmi

Director of Research Development,
Department of Health,
Abu Dhabi, UAE



Dr. David Dennison

Consultant, Hematology and
Bone Marrow Transplant
Abu Dhabi Stem Cells Center(ADSCC)
Abu Dhabi, UAE



Dr. Eman Rashid Mohamed Taryam Alshamsi

Consultant and acting head of Pediatric
Hematology oncology
Al Jalila children specialty hospital
Dubai, UAE



Dr. Mohammad Fahed Abdullah

Consultant Pediatric Hematologist Oncologist,
Burjeel Medical City, Abu Dhabi, UAE



SCIENTIFIC COMMITTEE



Dr. Mohammed Al Nuaimi

Consultant Physician, Pediatric Hematology and Oncology, Bone Marrow Transplant and Cellular Therapy, Sheikh Khalifa Medical City, & Adjunct Assistant Professor, College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, UAE



Dr. Mohammed Ramzan

Pediatric Hematologist - Oncologist and BMT
Burjeel Medical City, Abu Dhabi, UAE



Dr. Zainul Aabideen

CCT(UK), FRCPCH
Conference Chair
Chairman Organising & Scientific Committee
Consultant and Head of Pediatric Haematology, Oncology & BMT, Burjeel Medical City Abu Dhabi, UAE



Dr. Najam Awan

Consultant Pediatric Hematologist Oncologist,
Tawam Hospital, Al Ain, UAE



Dr. Mehran Karimi

Professor Emeritus of Pediatric Hematology and Oncology
Consultant Pediatric Hematologist-Oncologist
American Hospital Dubai, UAE



Dr. Layla Ali Eisa Mohamed Alreymi

Consultant Physician
Hematology/Oncology
Tawam Hospital, Al Ain, UAE



Dr. Anjan Madasu

Pediatric hemato-oncologist & BMT Physician
Al Jalila Children's Hospital, Dubai, UAE



Dr. Abdul Hakim Al-Rawas

President, Omani Society of Hematology(OSH), Senior Consultant, Pediatric Hematology/Oncology & HSCT, Department of Child Health, Sultan Qaboos University Hospital, Oman



Dr. Funda Cipe

Pediatric Allergy Immunology Subspecialist
Al Qassimi Women's & Children's Hospital, Sharjah, UAE



Dr. Charbel Khalil

Cell Therapy Lab Director Reviva Regenerative Medicine Center, Bsalm, Lebanon
Cell Therapy Lab Director Burjeel Medical City, Abu Dhabi, UAE, Assistant Professor Lebanese American University of Beirut School of Medicine Lebanon



Dr. Zohreh Nademi

Specialist in Pediatric Immunology and Stem Cell Transplant
Deputy Director of Children's Transplant Clinical Programme Great North Children's Hospital
Honorary Clinical Senior Lecturer in the Translational and Clinical Research Institute, Newcastle University, UK



Prof. Faisal M. Khan

Professor, Cumming School of Medicine, University of Calgary, Canada
CEO, OncoHelix-Colab, Abu Dhabi, UAE
Clinical Director, Hematology Translational Lab, University of Calgary, Canada



INTERNATIONAL ADVISORY BOARD



Dr. Lawrence Faulkner

Pediatric Hematologist-Oncologist & Bone Marrow Transplant Specialist
Cure2Children Foundation, Florence, Italy



Dr. Fulvio Porta

Senior Consultant & Director
Pediatric Oncohaematology and BMT Unit
Children's Hospital, Spedali Civili,
Brescia, Italy



Prof. Andrew R Gennery

Professor of Paediatric Immunology & HSCT
Honorary Consultant
Newcastle University and
Great North Children's Hospital, UK



Dr. Amr Abdalla Salem Dahdouh

Consultant of Pediatric Hematology/
Oncology and HSCT
Sultan Qaboos University
Muscat, Oman



Dr. Alaa Elhaddad

Head of the Pediatric Oncology Department
and the Bone Marrow Transplant Unit at the
Children's Cancer Hospital Cairo Egypt,
Former Dean of the National Cancer Institute
Cairo University, Egypt



Dr. Michael Grimley

Professor of Clinical Pediatrics,
Medical Director, Bone Marrow Transplant
and Immune Deficiency, Cincinnati
Children's Hospital Medical Center, USA



Dr. Rawad Suleiman Rihani

Chairperson, Department of Pediatrics,
Pediatric Blood & marrow Transplantation
and Cellular Therapy
King Hussein Cancer Center
Amman- Jordan



Dr. Sunil Bhat

Vice-Chairman, Oncology Collegium,
Narayana Health Group of Hospitals,
Director & Clinical Lead Pediatric Hematology,
Oncology, & Blood & Marrow Transplantation,
Narayana Health Network Hospitals -
SRCC NH Children's Hospital, Mumbai, India
Mazumdar Shaw Cancer Centre,
Narayana Health City Bangalore, India



Dr. Mohammad Alshahrani

Consultant Pediatric Hematology/
Oncology and BMT,
Prince Sultan Military Medical City,
Saudi Arabia, Riyadh



Dr. Sondus Ibrahim AlSharidah

Chairman of Pediatric Haematology Oncology
Department, Head of SCT Unit,
NBK specialized Children's Hospital, Kuwait



Dr. Ayman Saleh

Division Chief of Pediatric Hematology,
Oncology & BMT,
Sidra, Medicine, Doha, Qatar



Prof. Djamila Polatova

Director General
The Center for Pediatric Hematology,
Oncology and Clinical Immunology
Tashkent, Uzbekistan



Prof. Miguel R. Abboud

Professor of Paediatrics (Haematology Oncology)
Chairman of the Department of Paediatrics
and Adolescent Medicine
American University of Beirut (AUB)
Medical Centre, Beirut, Lebanon



Dr. Gaurav Kharya

Director Centre for Bone Marrow Transplant
& Cellular Therapy
Indraprastha Apollo Hospital
Delhi, India



Dr. Rabi Hanna

Chair, Department of Pediatric Hematology-
Oncology and Blood & Marrow Transplantation
Director of Pediatric BMT program
Cleveland Clinic, Cleveland Clinic Children's
Cleveland, Ohio, US



Dr. Abdul Hakim Al-Rawas

President, Omani Society of
Hematology(OSH), Senior Consultant,
Pediatric Hematology/Oncology & HSCT,
Department of Child Health,
Sultan Qaboos University Hospital, Oman



SPEAKERS



Prof. Stephan A. Grupp

Chief Cellular Therapy and Transplant Section
Professor of Pediatrics
Children's Hospital of Philadelphia &
University of Pennsylvania School of Medicine
Philadelphia, USA



Prof. Shahrukh Khurshid Hashmi

Director of Research Development,
Department of Health,
Abu Dhabi, UAE



Prof. Andrew R Gennery

Professor of Paediatric Immunology & HSCT
Honorary Consultant
Newcastle University and
Great North Children's Hospital, UK



Dr. Stephan Kadauke

Assistant Professor of Clinical Pathology
and Laboratory Medicine, Associate Director
of the Cell and Gene Therapy Laboratory
Children's Hospital of Philadelphia &
University of Pennsylvania School of Medicine
Philadelphia, United States



Dr. Kasiani C. Myers

Professor of Pediatrics
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States



Dr. Rabi Hanna

Chairman, Department of Pediatric
hematology-oncology and BMT
Cleveland Clinic
United States



Prof. Sonali Chaudhury

Director, Stem Cell Transplantation
and Cellular Therapies,
Ann & Robert H. Lurie Children's
Hospital of Chicago
Chicago, United States




Dr. Paibel Aguayo-Hiraldo

Clinical Director, Transplant and
Cellular Therapy Section
Children's Hospital Los Angeles
Los Angeles, California, United States



Dr. Kevin O. McNerney

Attending Physician, Hematology,
Oncology, Neuro-Oncology,
and Stem Cell Transplantation,
Ann & Robert H. Lurie Children's Hospital of
Chicago, Chicago, United States



Dr. Baheyeldin M. Salem

Associate Professor of Pediatrics
Division of Pediatric Hematology/Oncology
Texas Children's Hospital
United States




Dr. Júlia Marsal Ricomà

Head of the Bone Marrow Transplantation Unit
SJD Barcelona Children's Hospital
Barcelona, Spain



Dr. Fulvio Porta

Senior Consultant & Director
Pediatric Oncohaematology and BMT Unit
Children's Hospital, Spedali Civili,
Brescia, Italy



Dr. Mahmoud Hammad

Professor of Pediatric Oncology &
Stem Cell Transplant
National Cancer Institute
Cairo University, Egypt



Prof. Miguel R. Abboud

Professor of Paediatrics (Haematology Oncology)
Chairman of the Department of Paediatrics
and Adolescent Medicine
American University of Beirut (AUB)
Medical Centre, Beirut, Lebanon



SPEAKERS



Dr. Mohammed Faud Essa

Pediatric Hematologist and Oncologist
King Abdullah Specialist Children Hospital
Ministry of National Guard
Riyadh, Saudi Arabia



Dr. Muhammad Faisal Khanani

Co -chair of organizing committee
Chief, Division of Pediatric Hematology
and Oncology, Consultant Pediatric Oncology
Tawam Hospital, Al Ain, UAE



Prof. Dr. Rupert Handgretinger

Conference Co-Chair, Chairman Scientific committee
Prof. emeritus, Children's University Hospital, Germany
George and Jennifer Yeo Endowed Chair for
Pediatric Hematology, National University Singapore;
Consultant, Abu Dhabi Stem Cells Center (ADSCC)
and Yas Clinic Khalifa City (YCKC), Abu Dhabi, UAE



Dr. Zainul Aabideen

CCT(UK), FRCPCH, Conference Chair
Chairman Organising & Scientific Committee
Consultant and Head of Pediatric Haematology,
Oncology & BMT,
Burjeel Medical City Abu Dhabi, UAE




Dr. Santanu Sen

Senior Consultant & HOD
Pediatric Hematology, Oncology & BMT
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India



Dr. Satya Prakash Yadav

Director - Pediatric Hematology Oncology &
BMT Medanta - The Medicity,
Gurgaon, India



Dr. Sondus Ibrahim AlSharidah

Chairman of Pediatric Haematology Oncology
Department, Head of SCT Unit,
NBK specialized Children's Hospital, Kuwait



Dr. Jeanne Jihane Toughza

Professor of Medicine
Head of the Pediatric Oncology and
Hematology Department
University Hospital in Casablanca
Morocco



Prof. Fouzia Nambiatheyil Aboobacker

Co-Chair of scientific committee
Professor of Hematology
Consultant Pediatric Hematology
Department of Hematology,
Burjeel Medical City, Abu Dhabi, UAE



Dr. Intezar Mehdi

Director and Head of the Department,
Senior Consultant - Paediatric Haematology
Oncology and BMT
HCG Cancer Centre, Bangalore, India



Prof. Faisal M. Khan

Professor, Cumming School of Medicine,
University of Calgary, Canada
CEO, OncoHelix-Colab, Abu Dhabi, UAE
Clinical Director, Hematology Translational Lab,
University of Calgary, Canada



Dr. Gaurav Kharya

Director Centre for Bone Marrow Transplant
& Cellular Therapy
Indraprastha Apollo Hospital,
Delhi, India



SESSION CHAIR



Prof. Dr. Rupert Handgretinger

Conference Co-Chair, Chairman Scientific committee
Prof. emeritus, Children's University Hospital, Germany
George and Jennifer Yeo Endowed Chair for
Pediatric Hematology, National University Singapore;
Consultant, Abu Dhabi Stem Cells Center (ADSCC)
and Yas Clinic Khalifa City (YCKC), Abu Dhabi, UAE



Dr. Fatheya Abbas Al-khaja

Director of Dubai Thalassemia Center
Dubai Health
Dubai, UAE



Dr. Ibrahim Al Ghaithi

Consultant, Department of Pediatric
Hematology Oncology
Director, Innovation Program,
Oman E-Health Strategy
The Royal Hospital Muscat, Oman



Dr. Sagar Mohan Nivargi

Specialist - Department of Pediatric
Hematology Oncology & Bone Marrow
Transplantation, Burjeel Medical City,
Abu Dhabi, UAE



Dr. Mohammed Al Nuaimi

Consultant Physician, Pediatric Hematology
and Oncology, Bone Marrow Transplant and
Cellular Therapy, Sheikh Khalifa Medical City,
& Adjunct Assistant Professor,
College of Medicine and Health Sciences,
United Arab Emirates University
Abu Dhabi, UAE




Dr. Mohammed Ramzan

Pediatric Hematologist -
Oncologist and BMT
Burjeel Medical City, Abu Dhabi, UAE



Dr. Funda Cipe

Pediatric Allergy Immunology Subspecialist
Al Qassimi Women's & Children's Hospital,
Sharjah, UAE



Prof. Hanan Fawzy Nazir Abouelkhel

Professor of Pediatric Hematology,
Alexandria University, Consultant and
head of pediatric hematology unit,
Al Qassimi Women and Children Hospital
Sharjah, UAE



Dr. Vikas Dua

Principal Director & Head
Pediatric Hemato Oncologist and BMT Specialist
Fortis Memorial Research Institute
Delhi, India



Dr. Hiba Shendi

Consultant Immunologist/Allergist
Tawam Hospital,
Al Ain, UAE



Dr. Somaya Al Nuaimi

Pediatric Consultant
Arab Board Residency Program Deputy
Head of Thalassemia Department
Fujairah Hospital, EHS Arab Board Pediatric
Associated Professor, Ras Al Khaimah
Medical and Health Sciences University, UAE




Dr. Rasmi Palassery

Associate Professor,
Dept. of Medical Oncology
Ramaiah Medical College
Bengaluru, India



SESSION CHAIR



Dr. Ibraheem Abosoudah

Director of Pediatric Hematopoietic Stem Cell Transplant Program
Consultant Pediatric Hematology Oncology and Stem Cell Transplant
King Faisal Specialist Hospital & Research Centre
Jeddah, Saudi Arabia



Dr. Santanu Sen

Senior Consultant & HOD
Pediatric Hematology, Oncology & BMT
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India



Dr. Gaurav Kharya

Director Centre for Bone Marrow Transplant & Cellular Therapy
Indraprastha Apollo Hospital,
Delhi, India



Dr. Krish Venkatesh

Consultant Pediatric Gastroenterology
Burjeel Medical City
Abu Dhabi, UAE



Dr. Ayman Saleh

Chief, Pediatric Hematology-Oncology & BMT
Sidra Medicine
Doha, Qatar



Dr. Hanafy Ahmed Mohamed Hafez

Professor of Pediatric Oncology and BMT
National Cancer Institute, Cairo University
Cairo, Egypt



Dr. Jalila Al Kendi

Paediatric Hematology / Oncology Consultant
National Oncology Centre
Royal Hospital, Oman



SCIENTIFIC PROGRAM

DAY 1: Saturday – 09 November 2024

TIME	TOPIC	SPEAKER
07:50-08:50	Registration	
08:50-09:00	Welcome Speech	
SESSION 1 Moderator: Prof. Rupert Handgretinger, Dr. Sagar Mohan Nivargi, Dr. Ibrahim Al Ghaithi		
09:00-09:25	BMT in children UAE Experience	Dr. Zainul Aabideen UAE
09:25-09:50	Bone Marrow Transplant in Egypt: Advancements, Offerings, and Unmet Needs	Dr. Mahmoud Hammad Egypt
09:50-10:15	"Clinical Trials in Cell and Gene Therapy - are the scientists, regulators, pharmaceuticals, and entrepreneurs aligned?"	Prof. Shahrukh Khurshid Hashmi UAE
10:15-10:25	Panel Discussion	
10:25-10:55	OFFICIAL INAUGURATION	
10:55-11:10	Coffee Break	
SESSION 2 Moderator: Dr. Mohammed Al Nuaimi, Dr. Somaya Al Nuaimi		
11:10-11:40	SYMPOSIUM:- Gene Editing for Haemoglobinopathies	Dr. Sondus Ibrahim AlSharidah Kuwait
11:40-12:05	CAR T cell Therapy for pediatric solid tumors	Dr. Baheyeldin M. Salem USA
12:05-12:30	HLH-like toxicities after CAR T-cell therapy	Dr. Kevin O. McNerney USA
12:30-12:55	Accelerating Global Access to Point of Care Cell Therapy	Dr. Stephan Kadauke USA
12:55-13:05	Panel Discussion	
13:05-14:00	Lunch Break	
SESSION 3 Moderator: Dr. Ibraheem Abosoudah, Dr. Gaurav Kharya		
14:00-14:25	Ex vivo gene therapy for hemoglobinopathies: beginning commercial access	Prof. Stephan Grupp USA
14:25-14:50	Rewriting the Code ; Advances and Challenges in Gene Therapy for Sickle Cell Disease	Dr. Rabi Hanna USA
14:50-15:15	ExtraCorporeal Photopheresis in Pediatric patients?	Prof. Andrew R Gennery UK
15:15-15:25	Panel Discussion	
15:25-15:35	Break	
SESSION 4 Moderator: Dr. Rasmi Palassery , Dr. Fatheya Abbas Al-Khaja		
15:35-16:00	BMT in Children Lebanon Experience	Prof. Miguel R. Abboud Lebanon
16:00-16:25	Umbilical cord blood transplant for non-malignant disorders	Dr. Paibel Aguayo-Hiraldo USA
16:25-16:50	HSCT for SCD in Resource Constraint Setting: Lessons Learnt from India	Dr. Gaurav Kharya India
16:50-17:00	Panel Discussion	
17:00	End of Day 1	

SCIENTIFIC PROGRAM

DAY 2: Sunday – 10 November 2024

TIME	TOPIC	SPEAKER
07:50-08:50	Registration	
08:50-09:00	Welcome Speech	
SESSION 5 Moderator: Dr. Hanafy Ahmed Hafez, Dr. Krish Venkatesh		
09:00-09:25	Biomarkers for acute Graft versus host disease- Diagnostic, prognosis, and predictive values. Are we there yet?	Dr. Paibel Aguayo-Hiraldo USA
09:25-09:50	BMT in Children Morocco Experience	Dr. Jeanne Jihane Toughza Morocco
09:50-10:15	The importance of post-transplant chimerism analysis	Prof. Dr. Rupert Handgretinger UAE
10:15-10:25	Panel Discussion	
10:25-10:40	Coffee Break	
SESSION 6 Moderator: Dr. Hiba Shendi, Dr. Funda Cipe, Dr. Santanu Sen		
10:40-11:05	SYMPOSIUM:- Preventing hearing loss in children treated with cisplatin: an introduction to Pedmark	Dr. Muhammad Faisal Khanani UAE
11:05-11:30	Management of VOD/SOS After Allogeneic HSCT in Children	Dr. Intezar Mehdi India
11:30-11:55	Long term complications, follow up and transition of pediatric patients to adults units	Dr. Júlia Marsal Ricomà Spain
11:55-12:20	BMT for Inborn Errors of Immunity	Dr. Santanu Sen India
12:20-12:45	Haploidentical BMT in Neuroblastoma	Dr. Fulvio Porta Italy
12:45-12:55	Panel Discussion	
12:55-14:00	Lunch Break	
SESSION 7 Moderator: Dr. Ayman Saleh, Prof. Hanan Fawzy Nazir Abouelkhel		
14:00-14:25	CAR T cell Therapy for pediatric leukemias	Dr. Baheyeldin M. Salem USA
14:25-14:50	Stem cell transplantation in sickle cell disease: Experience From Saudi Arabia	Dr. Mohammed Faud Essa Saudi Arabia
14:50-15:15	Haploidentical BMT for Thalassemia	Dr. Satya Prakash Yadav India
15:15-15:40	HSCT in Gaucher Disease in Children	Prof. Fouzia Nambiatheyil Aboobacker UAE
15:40-15:50	Panel Discussion	
15:50-16:00	Break	
SESSION 8 Moderator: Dr. Mohammed Ramzan, Dr. Vikas Dua & Dr. Jalila Al Kendi		
16:00-16:25	Gene therapy in Beta Thalassemia	Prof. Sonali Chaudhury USA
16:25-16:50	Early and Accurate prediction of AML relapse after allogeneic HCT- A tale of two contrasting molecular approaches	Prof. Faisal M. Khan UAE
16:50-17:15	Bone Marrow Failure: 2024 update	Dr. Kasiani C. Myers USA
17:15-17:25	Panel Discussion	
17:25-17:30	Closing Remarks	
17:30	End of Day 2	

3rd EMIRATES PEDIATRIC BONE MARROW TRANSPLANT & GENE THERAPY CONGRESS

9-10 November 2024 - Grand Hyatt Hotel, Abu Dhabi, UAE

GENERAL INFORMATION

VENUE

Grand Hyatt Abu Dhabi Hotel & Residences Emirates Pearl offers a 5 star luxury hotel and events venue of awe-inspiring design and extraordinary architecture, located in the iconic West Corniche district of Abu Dhabi.

NAME TAGS

Participants are required to wear their name tags throughout the meeting in order to be admitted to the lecture halls and other scheduled activities.

REFRESHMENT AND LUNCH

Refreshment and lunch will be offered in accordance with the breaks indicated on the Agenda.

CYBER INTERNET

Free internet will be available in the exhibition area during the conference.

MOBILE PHONES AND PHOTOGRAPHY

Participants are kindly requested to keep their mobile phones silent mode in the conference hall and refrain from taking photographs during sessions.

CME ACCREDITATION

The 3rd Emirates Pediatric Bone Marrow Transplant & Gene Therapy Congress has been accredited by the Department of Health and is designated for a maximum of **15.10 DOH (CME)** credits. Delegates based in UAE, are required to claim their certificate through the DOH TAMM application. The certificate will be available for claim within 60 days from the conference start date.

DAY 1, Saturday 9/11/2024 is Accredited for 7.6 CME Hours

DAY 2, Sunday 10/11/2024 is Accredited for 7.5 CME Hours

The 3rd Emirates Pediatric Bone Marrow Transplant & Gene Therapy Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and is designated for a maximum of **14.50 European CME** credits (ECMEC®s). EACCME® certificates of attendance will be ready maximum 7 days post conference at MENA Conference website (www.menaconference.com).

DAY 1, Saturday 9/11/2024 is Accredited for 7.5 CME Hours

DAY 2, Sunday 10/11/2024 is Accredited for 7.0 CME Hours

CERTIFICATE OF ATTENDANCE

- A notification containing the link and instructions on how to download the certificates will be sent to your registered email address.
- Please note that you are required to complete the online evaluation of the conference before you can access the link to download your CME certificates. It is your responsibility to download and retain a copy of the certificate for your records.
- Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

SPEAKERS' BIOGRAPHY

SPEAKERS' BIOGRAPHY



Prof. Stephan Grupp

Chief Cellular Therapy and Transplant Section
Professor of Pediatrics
Children's Hospital of Philadelphia &
University of Pennsylvania School of Medicine
Philadelphia, USA



Stephan A. Grupp, MD, PhD, is Section Chief of the Cellular Therapy and Transplant Section, Inaugural Director of the Susan S and Stephen P Kelly Center for Cancer Immunotherapy, and Medical Director of the Cell and Gene Therapy Laboratory and Children's Hospital of Philadelphia.

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.

The primary focus of Dr. Grupp's research is the development of targeted and cell therapies and study of molecular signaling pathways in acute lymphoblastic leukemia (ALL). His group has leveraged studies using primary human ALL xenografts into treatments tested in a number of clinical trials, including national phase III randomized and FDA registration trials.

As part of his role as medical director of the stem cell lab at Children's Hospital of Philadelphia and transplant discipline chair for the Children's Oncology Group (COG), Dr. Grupp and his team have performed trials to improve outcomes in neuroblastoma. His team developed tandem transplant approaches at CHOP, piloted them in the COG and then designed a national phase III trial (ANBL0532) in the COG, the results of which are positive.



Prof. Shahrukh Khurshid Hashmi

Director of Research Development,
Department of Health,
Abu Dhabi, UAE



Professor of Medicine (Transplant Center), Mayo Clinic Alix School of Medicine, Minnesota, US

Adjunct Professor of Computer Vision, MBZ-University of Artificial Intelligence, Abu Dhabi, UAE

Dr. Hashmi graduated as the top student from Baqai Medical University, Pakistan, earning a Gold Medal from the President of Pakistan. He later obtained his Master's in Public Health (MPH) from Yale University, Connecticut, US. He is a triple-boarded diplomat from the US in Preventive Medicine/Public Health, Internal Medicine, and Hematology.

Dr. Hashmi has held multiple prestigious roles, including Principal Investigator (PI) or Co-PI on various industry and NIH-sponsored trials. His research focuses on premature aging biology, artificial intelligence, and cellular therapies, such as CAR-T cells and gene therapy. He is also active in regenerative hematology and stem cell therapeutics.

With over 320 peer-reviewed articles, including publications in JAMA Oncology, Lancet Hematology, and New England Journal of Medicine (NEJM), Dr. Hashmi's work has garnered more than 11,000 citations.

He chairs several prominent professional committees, including the Worldwide Network for Blood and Marrow Transplant's (WBMT) Global Emergencies Committee (Geneva, Switzerland) and the American Society for Transplantation and Cellular Therapy's Survivorship SIG (Chicago, Illinois, US). He has also served as Co-Chair of the Center for International Blood & Marrow Transplant Registry's (CIBMTR) Health Services Committee (Milwaukee, Wisconsin, US).

Dr. Hashmi's career includes leading the first Bone Marrow Transplant Survivorship Program at Mayo Clinic in Minnesota and founding Clinical Trials Units (CTU) in Saudi Arabia and the UAE. His research in senolytics has led to First-in-Human trials approved by the US-FDA.

As a leading scientist in Cell & Gene Therapy, Aging Biology, and Artificial Intelligence, Dr. Hashmi has delivered over 80 invited lectures globally and sits on the boards of several organizations, including Make-A-Wish Foundation UAE and the Cancer Patient Care Society (Rahma) UAE. He is also the Associate Editor of Journal of Transplantation and Cellular Therapy (JTCT) and serves on editorial boards of various peer-reviewed journals.

SPEAKERS' BIOGRAPHY



Prof. Andrew R Gennery

Professor of Paediatric Immunology & HSCT
Honorary Consultant
Newcastle University and
Great North Children's Hospital, UK



I am Professor in Paediatric Immunology and HSCT at Newcastle University and Honorary Consultant for the Northern National HSCT Unit for IEI, at Great North Children's Hospital, Newcastle. I spent a year working at the Necker Hospital, Paris, involved in the discovery of Cytidine Deaminase – critical for class switch recombination and somatic hypermutation.

Research interests include immunoreconstitution following HSCT for IEI, long-term outcomes of transplantation for IEI, appropriate treatment of DNA repair disorders, and Di George Syndrome. I have established ECP for treatment of paediatric GvHD and discovered mechanistic insights relating to ECP mode of action, and am exploring the use of defibrotide for treatment of non-VOD endothelial cell activation disorders post-HSCT.

I am a member of ESID and EBMT, recently chaired ESID/EBMT IEWP, ESID CWP, ERN-RITA Guidelines Working Party, and CIBMTR PID IEM and other NMMD Working Committee. I have published >420 papers on primary immunodeficiency, co-authored multi-centre publications on outcomes of cohorts of children with IEI following HSCT, and contributed relevant chapters in major textbooks. I have co-authored national guidelines on management of 22q11 deletion syndrome, use of ECP for treatment of aGvHD, and international guidelines for treatment of DNA repair disorders and CD40 ligand deficiency. I am clinical lead for the SCID NBS pilot in England.



Dr. Stephan Kadauke

Assistant Professor of Clinical Pathology and Laboratory Medicine,
Associate Director of the Cell and Gene Therapy Laboratory
Children's Hospital of Philadelphia & University of Pennsylvania School of Medicine
Philadelphia, USA



Dr. Stephan Kadauke is an Assistant Professor of Clinical Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine and serves as the Associate Director of the Cell and Gene Therapy Laboratory at the Children's Hospital of Philadelphia (CHOP). Dr. Kadauke has extensive experience in the clinical development and implementation of GMP-compliant engineered cell therapies. He is deeply involved in over 60 active cell therapy clinical trials and co-leads a project to build a new GMP Cell Therapy manufacturing facility. His work has significantly advanced the field of cell and gene therapies, particularly through developing innovative processes for CAR-T cell manufacturing.

Dr. Kadauke also serves as attending physician on the Apheresis service, where he treats patients with sickle cell disease and various autoimmune and neurological diseases. He also supervises cell collections for patients who require stem cell transplantation or other cellular immunotherapies.

In addition to his clinical work, Dr. Kadauke is the medical director of Cell and Gene Therapy Informatics (CGTI). CGTI is an agile team that builds systems to deliver reliable, high-quality, and timely data to Cell and Gene Therapy clinicians and researchers to help clinical decision making, improve and automate quality operations, and accelerate Cell and Gene Therapy clinical research.

SPEAKERS' BIOGRAPHY



Dr. Kasiani C. Myers

Professor of Pediatrics
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States



Dr. Kasiani Myers is a Professor of Pediatrics in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's Hospital Medical Center within the University of Cincinnati Department of Pediatrics. In her clinical practice, she specializes in treating patients with bone marrow failure and hematopoietic stem cell transplant for non-malignant diseases, with a special emphasis on Shwachman Diamond syndrome and Telomere Biology Disorders. Her research focuses on translational and clinical studies in leukemogenesis and bone marrow failure related to these two conditions as well as complications of HSCT, including bronchiolitis obliterans and fertility preservation. She is the Principal investigator of an industry sponsored first in human gene therapy trial for telomere elongation in patients with Telomere Biology disorders and is the co-director of the North American Shwachman Diamond Syndrome Registry.



Dr. Rabi Hanna

Chairman, Department of Pediatric
hematology-oncology and BMT
Cleveland Clinic
United States



Rabi Hanna, MD is the Chairman of Pediatric hematology-oncology Division at Cleveland Clinic.

Dr. Hanna earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria. His post-graduate training in USA included residency at Duke University and a pediatric hematology-oncology and BMT fellowship at the Fred Hutchinson Cancer Research Center and Seattle Children's Hospital in Seattle, Washington. He moved to Cleveland Clinic in 2011 where he serves as the and is the Director of the Pediatric Transplant, Cell & Gene Therapy at Cleveland Clinic Children's Hospital he is an Associate Professor at Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University and has Jerome and Lee Burkons Endowed Research Chair.

Dr. Hanna has published several research articles in peer-reviewed journals, and has presented at professional association meetings. His specialty interests include Transplant and Gene therapy for inherited non-malignant disorders like primary immunodeficiency, inherited metabolic diseases and blood disorders (like thalassemia and sickle cells disease)

SPEAKERS' BIOGRAPHY



Prof. Sonali Chaudhury

Director, Stem Cell Transplantation
and Cellular Therapies,
Ann & Robert H. Lurie Children's
Hospital of Chicago
Chicago, United States



Dr. Sonali Chaudhury currently serves as the Director of Stem Cell Transplantation and Cellular Therapies at Ann & Robert H. Lurie Children's Hospital of Chicago, and is also a Professor of Pediatrics, Hematology, Oncology, and Stem Cell Transplantation at Northwestern University's Feinberg School of Medicine.


She earned her medical degree from B.J. Medical College, University of Poona, India in 1993 and subsequently completed her postgraduate training at Memorial Sloan Kettering Cancer Center in New York. Her specialized training includes a Fellowship in Pediatric Stem Cell Transplant (2006-2007), a Fellowship in Pediatric Hematology/Oncology (2003-2006), and a Pediatrics Residency at New York Presbyterian Hospital (Cornell Campus) in 2002-2003.

Dr. Chaudhury is board-certified in Pediatric Hematology-Oncology and actively contributes to several professional organizations, including the American Academy of Pediatrics and the American Society of Pediatric Hematology Oncology.

In her current role, Dr. Chaudhury leads the Pediatric Stem Cell Transplant and Cellular Therapy section and holds key leadership positions in the PTCTC and COG study groups. Her primary focus is on clinical trials aimed at reducing toxicities and improving outcomes in stem cell transplants, particularly for non-malignant disorders and Pediatric Chronic Myeloid Leukemia (CML).

Academic Focus: Dr. Chaudhury specializes in leading clinical research efforts, specifically in designing and implementing clinical trials to enhance stem cell transplant outcomes.

Clinical Focus: Her expertise includes Chronic Myeloid Leukemia, transplantation for hematological non-malignant disorders, and advancing cellular-immunotherapy for malignancies.



Dr. Paibel Aguayo-Hiraldo

Clinical Director, Transplant and
Cellular Therapy Section
Children's Hospital Los Angeles
Los Angeles, California, United States



Dr. Paibel Aguayo-Hiraldo is an accomplished pediatric hematologist-oncologist and bone marrow transplant specialist. She earned her M.D. from San Juan Bautista School of Medicine in Caguas, completed her residency in Internal Medicine-Pediatrics at the University of South Florida, followed by fellowships in Pediatric Hematology-Oncology and Bone Marrow Transplant at Baylor College of Medicine and Texas Children's Hospital. As an Assistant Professor at USC, she continues to make significant contributions to the field, focusing on complications post-bone marrow transplant, including GVHD and adoptive immunotherapy to treat viral infections in the immunocompromised host. Her clinical interests include hematopoietic stem cell transplant for immunodeficiencies, immune dysregulation disorder, and other non-malignant disorders. Dr. Aguayo-Hiraldo is board-certified in Internal Medicine, Pediatrics, and Pediatric Hematology and Oncology and currently serves as the Clinical Director for the Transplantation and Cellular Therapy section of the Cancer and Blood Diseases Institute at Children's Hospital Los Angeles the University of Southern California Keck School of Medicine.

SPEAKERS' BIOGRAPHY



Dr. Kevin O. McNerney

Attending Physician, Hematology,
Oncology, Neuro-Oncology, and Stem Cell Transplantation,
Ann & Robert H. Lurie Children's Hospital of Chicago,
Chicago, United States



Attending Physician, Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago

Assistant Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation), Northwestern University Feinberg School of Medicine

Kevin McNerney, MD, specializes in blood and marrow transplantation (BMT) and cancer immunotherapy with a clinical focus on chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed and refractory leukemia. Dr. McNerney's research has focused on understanding the severe toxicities of CAR T-cell therapy and exploring mechanisms to improve outcomes for patients at the greatest risk of relapse. Dr. McNerney wishes to reduce toxicities and improve long-term disease-free survival for patients with high-risk malignancies.



Dr. Baheyeldin M. Salem

Associate Professor of Pediatrics
Division of Pediatric Hematology/Oncology
Texas Children's Hospital
United States



I am a US board-certified Pediatric Hematologist/Oncologist and a practicing Hematopoietic Cell Transplant (HCT) physician at Texas Children's Hospital (TCH). I am a member of the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine (BCM). My clinical research focus is on use of immunotherapies to improve the outcomes of patients with hematological malignancies. Under the mentorship of Dr. Nabil Ahmed at the CAGT, I have translated a highly innovative basic science research into a clinical study protocol using trivalent chimeric antigen receptor (CAR) T cell therapy for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) as the Principal Investigator (PI). My objectives for the next five years are to lead investigator-initiated clinical trials within my institution and on a multi-institutional or consortium level. Additionally, through collaboration with other investigator with the CAGT and at other institutions, I plan to incorporate biological studies of both, leukemia cells and CAR T- cells into our clinical trials to further elucidate on the dynamics of their interactions to enable targeting treatment-resistant leukemia cells more effectively in future trials.

SPEAKERS' BIOGRAPHY



Dr. Júlia Marsal Ricomà

Head of the Bone Marrow Transplantation Unit
SJD Barcelona Children's Hospital
Barcelona, Spain



Dr. Júlia Marsal Ricomà has been part of the SJD Barcelona Children's Hospital since June 2015 and has worked in the Bone Marrow Transplantation Unit since its establishment in January 2016. Prior to this, she completed her training in Haematology at Sant Pau Hospital and gained further experience at the Paediatric HSCT Unit at Memorial Sloan Kettering Hospital in New York.

Training:

Haematology residency at Santa Creu i Sant Pau Hospital, 2011 - 2015

Bachelor's Degree in Medicine from Rovira i Virgili University (URL), 2003 - 2009

International experience:

Training on Bone Marrow transplantation in the HSCT Unit at the Memorial Sloan Kettering Hospital, New York (United States), 2014.

Volunteer primary care physician in Paediatrics. Friends of Calcutta NGO. Rural area of Sunderbans, Kolkata (India), 2010.

Volunteer primary care physician, Paediatrics and Obstetrics. Collaboration between Rovira i Virgili University and the Spanish Milpa NGO in Guatemala, 2009.

Rotation in the Paediatric Department of the Allgemeines Krankenhaus Wien Hospital, Vienna (Austria). 2006 - 2007.



Dr. Fulvio Porta

Senior Consultant & Director
Pediatric Oncohaematology and BMT Unit
Children's Hospital, Spedali Civili,
Brescia, Italy



Senior Consultant and Director of the Clinical Unit at the Children's Hospital of Spedali Civili di Brescia, Italy, that is the second largest teaching hospital in Italy. The Unit has 26 beds, with 10 doctors, 30 nurses and 8 technicians. Children affected by immunological diseases (primary or secondary), oncohaematological diseases (leukemia, solid tumours, lymphoma, thalassemia, sickle cell diseases) are treated within the Unit. At present more than 700 bone marrow transplantation have been performed both from HLA compatible and partially matched donors, treated 3 children with CAR T cells

Education and qualification

15 July 1983 Medical Doctor Degree 1983, 1987 Specialization in Pediatrics, 1991 Specialization in Haematology

1986-90 Policlinico S. Matteo Pavia Italy permanent position


From July 1984 till March 1985 BMT coordinator in "Bud Flanagan Ward", Leukemia Unit, Royal Marsden Hospital Later that year I started the BMT Unit at the Paediatric Department of Pavia, Italy, assisting oncohaematological children realizing more than 100 BMT.

1990-2024 Spedali Civili Brescia Italy permanent position of Senior Consultant

More than 700 BMT performed. The Unit is National Referent Center for BMT in PID.

Dr. Porta covered the position of Secretary of the Inborn Errors EBMT Working Party 2006/2012; Presidency of the Italian Association of Pediatric Haematology and Oncology (AIEOP) 2010-2012; member of the Italian Foundation for Pediatric Oncohaematology (FIEOP); International Expert ASTER Hospital Bangalore India 2017/2019., International Expert Vinmec Institute, Hanoi, Vietnam, Ambassador for the International Society of Pediatric Oncology (SIOP) for the European Community

SPEAKERS' BIOGRAPHY




Dr. Mahmoud Hammad

Professor of Pediatric Oncology &
Stem Cell Transplant
National Cancer Institute
Cairo University, Egypt



Dr. Mahmoud Hammad is a pediatric oncologist with extensive clinical and research experience. He is currently Professor of Pediatric Oncology & Stem Cell Transplant at the National Cancer Institute of Egypt, Cairo University. He is the Director of Nasser Institute Oncology and Nuclear Center. He is the head of oncology department Kafr EL-Sheikh Cancer Center. Dr. Hammad is the Chair of education and training committee SIOP-Africa. He is member of the Supreme Council of Egyptian Ministry of Higher Education. He is senior consultant of oncology and Stem cell transplant at Dar Al-Fouad Hospital, Saudi German Hospital Egypt, Wadi El-neel Hospital, and Dar El-Salam Cancer center. He shared in establishing many pediatric stem cell transplant programs in Egypt including Children's Cancer Hospital Egypt (57357), Assiut university, Dar El-Salam Cancer center, Saudi German Hospital. His main interest is Leukemia, Juvenile Myelomonocytic Leukemia, MDS, CML and bone marrow failure disorders.



Prof. Miguel R. Abboud

Professor of Paediatrics (Haematology Oncology)
Chairman of the Department of Paediatrics and Adolescent Medicine
American University of Beirut (AUB)
Medical Centre, Beirut, Lebanon



Miguel R. Abboud is Professor of Paediatrics (Haematology Oncology) and Chairman of the Department of Paediatrics and Adolescent Medicine at the American University of Beirut (AUB) Medical Centre, Beirut, Lebanon. Dr Abboud also serves as the Director of the Children's Cancer Institute AUB. He obtained his medical degree and completed his paediatrics training at AUB, after which he undertook specialty training at the Memorial Sloan-Kettering Cancer Center and New York Hospital, Cornell University Medical Center in New York, NY, USA. Prior to joining AUB in 2002 he was a professor of paediatrics and director of the sickle cell program at the Medical University of South Carolina in Charleston, SC, USA. Dr Abboud has a long track record of research in sickle cell disease as the principal investigator in clinical trials he also served on several steering committees. Including the STOP, STOP II, preop transfusion and Baby HUG studies. Dr Abboud has received numerous awards and honours throughout his career, including the Lifetime Achievement Award from the Sickle Cell Disease Association of America and Physician of the Year from the National Committee for Lebanese Children.

SPEAKERS' BIOGRAPHY



Dr. Mohammed Faud Essa

Pediatric Hematologist and Oncologist
King Abdullah Specialist Children Hospital
Ministry of National Guard
Riyadh, Saudi Arabia



Dr. Mohammed Essa is a pediatric hematologist and oncologist at King Abdullah Specialist Children Hospital - Ministry of National guard in Riyadh, Saudi Arabia, where he serves as the Deputy Chairman of the Pediatric Hematology Oncology Department. He is also an Associate Professor at King Saud bin Abdulaziz University for Health Sciences

He completed his medical degree at King Saud University and pursued his residency and fellowships in Canada, alongside certifications from the Royal College of Physicians and Surgeons of Canada and the American Board of Pediatrics.

Dr. Essa area of interest is pediatric stem cell transplantation and cellular therapy including CART and Genetherapy. He also has contribution and collaboration with many centers to publish



Dr. Muhammad Faisal Khanani

Co -chair of organizing committee
Chief, Division of Pediatric Hematology
and Oncology, Consultant Pediatric Oncology
Tawam Hospital, Al Ain, UAE



Dr. Muhammad Faisal Khanani has served as the Chief of the division of pediatric hematology oncology since May 2014 and as a Consultant Pediatric Hematologist Oncologist at Tawam Hospital, Al Ain, UAE, since June 2005. In this role, he offers diagnostic services and specialized care for children under 15 years old with bleeding disorders, leukemia, lymphoma, and bone marrow transplants. Additionally, Dr. Khanani has held the position of Clinical Associate Professor at UAEU-FMHS in Al Ain, UAE, since May 2008. He is also actively involved in the Emirates Hematology Society, serving as the Vice President and chair of the hemophilia group. Furthermore, he has contributed to the field with over 25 publications in peer-reviewed journals.



Prof. Dr. Rupert Handgretinger

Conference Co-Chair, Chairman Scientific committee
Prof. emeritus, Children's University Hospital, Germany
George and Jennifer Yeo Endowed Chair for Pediatric Hematology, National University Singapore;
Consultant, Abu Dhabi Stem Cells Center (ADSCC) and Yas Clinic Khalifa City (YCKC), Abu Dhabi, UAE



Having received his MD from the University of Tübingen, Germany, Dr. Handgretinger was from 2005-2021 the chairman of the Department of General Pediatrics and Hematology / Oncology, Children's University Hospital of Tübingen, Germany. From 2000-2005, he was a professor of the Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, TN, USA; as well as a full faculty member and director of the Division of Stem Cell Transplantation, Department of Hematology / Oncology, St Jude Children's Research Hospital, Memphis, TN, USA. Since 2021, he is a consultant for Pediatric hematology/oncology at the Abu Dhabi Stem Cell Center and the Yas Clinic Khalifa City. His fields of interest are haploidentical stem cell transplantation, stem cell biology, and cellular and humoral immunotherapy.

SPEAKERS' BIOGRAPHY



Dr. Zainul Aabideen

CCT(UK), FRCPCH, Conference Chair
Chairman Organising & Scientific Committee
Consultant and Head of Pediatric Haematology, Oncology & BMT,
Burjeel Medical City Abu Dhabi, UAE



Education

MBBS, DCH FRCPCH (UK), MSc Oncology University of Birmingham (UK) CCT(UK), Fellowship Bone Marrow Transplantation (UK)

Dr. Zainul Aabideen is a Consultant in Pediatric Hematology, Oncology and BMT based in the United Arab Emirates.

Having gained his medical degree at Calicut University in Kerala, India, followed by his Post Graduation in Pediatrics from the University of Mumbai, He moved to the United Kingdom in 2001 to undertake further training in these areas.

Training & Employment in the UK

In the United Kingdom, Dr. Zainul Aabideen obtained a Masters degree in Pediatric Oncology at Birmingham University, a Postgraduate certificate in Medical Education at Manchester University, and completed an International Fellowship in Pediatric Bone Marrow Transplantation at the Great North Children's Hospital in Newcastle. He also received Certificate of Completion of Training (CCT).

He has gained further valuable experience in a number of high profile hospitals, including the Royal Marsden Hospital, University College of London Hospital, Imperial College Healthcare Centre in London; the Manchester Children's Hospital; Alder Hey Children's Hospital in Liverpool; the Queen's Medical Centre in Nottingham; and the Bristol Children's Hospital, before moving onto Consultant roles in both Manchester and Coventry.

During his time in the UK, Dr. Aabideen became a Fellow of the Higher Education Academy, Fellow of the Royal College of Pediatrics and Child Health in 2005, and a member of both the International Pediatric Oncology Organization (SIOP) and the UK Children's Cancer and Leukemia Group (CCLG).

Publications & Events

Dr. Aabideen is proud to have published articles in the fields of Pediatrics, Pediatric Hematology, and Oncology, in a variety of International Journals. Dr. Aabideen has also actively shared his knowledge with others by contributing towards international conference presentations all across the world, including events in India, Portugal, Spain, Italy, Australia, New Zealand, Jordan, Oman, Kuwait, Uzbekistan, UK and the USA. He has been the Chairman of the Emirate Pediatric Hematology and Oncology Conference in the last 6 years and Emirates Pediatric BMT Congress in the last 3 years.

Work in the United Arab Emirate

Following successful stint training and working in the United Kingdom, Dr. Aabideen moved to the United Arab Emirates in 2016. Dr. Aabideen worked at Burjeel Hospital in Abu Dhabi and Tawam Hospital Al Ain as Consultant Pediatric Oncology. He lead the team at Burjeel Medical City when first Pediatric BMT in the UAE performed at BMC in 2022."

SPEAKERS' BIOGRAPHY



Dr. Santanu Sen

Senior Consultant & HOD
Pediatric Hematology, Oncology & BMT
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India



Dr. Santanu Sen is a highly esteemed Senior Pediatric Hematologist and Oncologist, with a distinguished career specializing in pediatric cancers, blood disorders, and bone marrow transplantation. Having trained and worked at some of the world's leading hospitals, Dr. Sen brings over three decades of expertise in treating complex childhood cancers and hematological conditions, such as leukemia, lymphoma, and hemophilia. His dedication to cutting-edge treatment protocols, alongside his compassionate patient care, has earned him a reputation as a leader in his field.

As a pioneer in pediatric bone marrow transplantation, Dr. Sen has successfully led numerous complex procedures, pushing the boundaries of medical innovation to improve survival rates and quality of life for his young patients. In addition to his clinical excellence, Dr. Sen is an active researcher, contributing to advancements in cancer therapies and transplant medicine. His work is widely published in leading medical journals, and he is a sought-after speaker at international conferences. Dr. Sen remains deeply committed to mentoring the next generation of specialists and improving global pediatric care standards.




Dr. Satya Prakash Yadav

Director - Pediatric Hematology Oncology &
BMT Medanta - The Medicity,
Gurgaon, India



Dr. Satya Yadav treats children with blood and cancer disorders at Medanta Hospital, Gurugram, India. His clinical focus is primarily Paediatric Leukemia and Bone Marrow Transplantation (BMT). After finishing his training in Paediatrics from Delhi he went to Sydney, Australia, and worked as a fellow (2002-2005) in Paediatric Hemato-Oncology at The Children's Hospital at Westmead. He has an experience of over 20 years and he set up successful Paediatric BMT programs at Sir Ganga Ram Hospital, Fortis Gurgaon and Medanta Hospital. He along with his colleagues has been involved in performing over 1000 Blood & Marrow transplants and Cell Therapies. He has published in various national and international journals with over 1000 citations. He has been a teaching faculty for fellowship of National Board of Examinations (FNB) in Paediatric Hematology Oncology for >10 yr. He has trained more than 30 fellows in Paediatric Hematology Oncology who are working as consultants within and outside India.



Dr. Sondus Ibrahim AlSharidah

Chairman of Pediatric Haematology Oncology
Department, Head of SCT Unit,
NBK specialized Children's Hospital, Kuwait



Head of pediatric haematology oncology department.

Director of Paediatric SCT program in Kuwait, Head of paediatric SCT unit in NBK Children's Specialised Hospital, committee head for Stem Cell and tissue principles and technical and administrative standards. Head of committee for Central Policies for secondary and tertiary care, member of COVID-19 inspection team in MOH, Vice-president of SCD higher committee, president of Kuwait Paediatric association. Treasurer of Kuwait Thalassaemia league. Member of international bodies: EBMT, ISCT, ASTCT, ASHI, ARSHI. Graduated from Dublin, Ireland RCSI, double qualification for paediatrics (Kuwaiti board and MRCPCH), fellowship in paediatric haematology and SCT UK.

Established the paediatric SCT in 2020, initiated the treatment of CCP in Kuwait 2020. Research interest in the field of benign haematology, thrombosis haemostasis and stem cell transplantation.

SPEAKERS' BIOGRAPHY



Dr. Jeanne Jihane Toughza

Professor of Medicine
Head of the Pediatric Oncology and Hematology Department
University Hospital in Casablanca, Morocco



Dr. Jeanne Jihane Toughza is a distinguished physician and a leading figure in pediatric hematology and oncology in Morocco. She has notably launched the first allogeneic bone marrow transplant unit that meets international standards in the country, achieving over 15 successful operations since the beginning of 2022. Her contributions have earned her recognition as one of the 50 most influential women in Morocco.

In a significant milestone for Moroccan medicine, Dr. Toughza performed the first allogeneic bone marrow transplant at Cheikh Khalifa International University Hospital, as well as the first such transplant in Morocco for a young patient diagnosed with Fanconi anemia.

Since becoming a Referring Physician-Professor in Pediatric Hematology and Oncology in 2016, and later assuming the role of Medical Coordinator-Professor of Pediatric Allograft in 2019, Dr. Toughza has demonstrated an unwavering commitment to her patients. Her dedication extends beyond clinical practice; she actively participates in various associations and learned societies, contributing to the advancement of her field.

Dr. Toughza obtained her doctorate from the Faculty of Medicine in Poitiers, France, and specialized in Pediatrics, Hematology, Oncology, and Bone Marrow Allograft at renowned institutions in Lyon and Paris. She holds diplomas in Clinical Oncology as well as Acute and Chronic Pain and Palliative Care from the Faculty of Lyon. Additionally, she possesses a Master's degree in Molecular and Cellular Biology and a Master's degree in Bioethics. Her professional journey includes roles at the University Hospital of Bordeaux and the Léon Bérard-IHOPE Center in Lyon.

Dr. Toughza is not only a skilled clinician but also a compassionate advocate for her patients, embodying a commitment to care and support in her work.




Prof. Fouzia Nambiatheyil Aboobacker

Co-Chair of scientific committee
Professor of Hematology
Consultant Pediatric Hematology, Department of Hematology,
Burjeel Medical City, Abu Dhabi, UAE



Dr. Fouzia Nambiatheyil Aboobacker is a highly skilled and experienced hematologist with extensive expertise in pediatric hematology and stem cell transplantation. She began her medical journey by obtaining her Medical Degree (MBBS) in 1996, followed by a Diploma and a DNB degree in Child Health. Subsequently, Dr. Aboobacker joined the Department of Hematology at Christian Medical College, Vellore, as a Registrar and completed her Postgraduate degree in Clinical Hematology in August 2013. Demonstrating her commitment to excellence, she continued her journey at the same institution as an Assistant Professor, transitioning to the role of Professor in the Department of Hematology in January 2022. She has also worked in the UAE as a Consultant in Pediatric Hematology at ADSCC/Yas Clinic from December 2023 to July 2024. Throughout her career, Dr. Aboobacker has demonstrated exceptional proficiency in diagnosing and managing various malignant and non-malignant hematological disorders, including stem cell transplantation, CAR-T cell therapy, and gene therapy for hemophilia. She has a particular interest in primary immunodeficiency disorders, inherited metabolic disorders, red cell disorders, and disorders of hemostasis. Dr. Aboobacker's contributions extend beyond clinical practice, as she has actively engaged in national health education programs for hemophilia, sickle cell anemia, and hemoglobinopathies. She has served as a principal investigator and co-investigator for various research studies, including those on recombinant human coagulation factor VIII fusion protein and mutation analysis for hemolytic anemias. She is also the co-principal investigator for the DBT/Wellcome Trust India Alliance-granted project "Functional Assessment of Genetic Variants Associated with Fetal Hemoglobin Levels Using Base Editor-Mediated Saturated Mutagenesis for the Treatment of Beta Hemoglobinopathies." With over ten years of experience as a consultant, Dr. Aboobacker continues to play a pivotal role in managing complex hematological conditions, including stem cell transplantation, CAR-T cell therapy, and gene therapy, and contributes to the advancement of hematology research.

SPEAKERS' BIOGRAPHY



Dr. Intezar Mehdi

Director and Head of the Department,
Senior Consultant - Paediatric Haematology
Oncology and BMT
HCG Cancer Centre, Bangalore, India



MBBS, DNB (Pediatrics), MRCPCH(UK), FRCPC (UK)

Executive Committee Member- IAP BPS 2017, Executive Committee Member- IAP PHO Karnataka chapter-2017- until date

IAP-PHO CME- National Advisory Board, ISBMT- Membership Committee

- Faculty in Local, State, National and International conferences
- Areas of Interest : Hematolymphoid malignancies(Leukemia/Lymphoma), Thalassemias, Aplastic anemia, Bone tumors, solid tumors and BMT
- Reviewer : Indian Journal of Child Health, Indian Journal of Pediatrics, Indian Journal of case reports, Indian Journal of Palliative care
- Editor : Journal of Precision Oncology
- Life Member of IAP, IAP-BPS, RCPC, IAP-PHO chapter, IMA
- Member – Indian Society of Blood and Marrow transplant (ISBMT) , IPHOG, IAP- PHO (Karnataka), InPOG, SIOP- International Society for Paediatric Oncology
- Actively involved in Academic and social activities
- Faculty and Program Director- Fellowship in Pediatric hematology, oncology and BMT, HCG hospital, Bangalore
- Has publications in reputed journals, Presented various papers in National and international conferences
- PI for clinical trials



Prof. Faisal M. Khan

Professor, Cumming School of Medicine,
University of Calgary, Canada
CEO, OncoHelix-Colab, Abu Dhabi, UAE
Clinical Director, Hematology Translational Lab,
University of Calgary, Canada



Dr. Faisal M. Khan is a Professor at the University of Calgary. Dr. Khan is co-founder and CEO of OncoHelix Inc., an organization that specializes in providing esoteric cancer genomic and immunology testing.

In his clinical role, Dr. Khan works as the Director of Hematology Translational Lab at the University of Calgary; and as a Clinical Director of the Histocompatibility and Immunogenetic Lab (HIL) in Alberta Precision Labs.

Dr. Khan obtained his Ph.D. in Human Molecular Genetics in India in 2006. He completed his postdoctoral training and clinical fellowship at the University of Calgary. Dr. Khan is a certified Diplomat of the American Board of Histocompatibility and Immunogenetics (ABHI).

Dr. Khan has more than 21 years of experience in Transplant Immunology, Cancer Genomics, and Histocompatibility and Immunogenetics. Based on his research, Dr. Khan has published over 105 research articles in scientific journals like Science, Blood, Transplantation, and Blood Advances. His research has been recognized by several awards including the American Society of Hematology (ASH) Achievement Awards in 2013, 2015, and 2018; and the American Society for Histocompatibility and Immunogenetics (ASHI) Scholar/Most Clinically Relevant Study awards in 2014, 2019, and 2022.

SPEAKERS' BIOGRAPHY



Dr. Gaurav Kharya

Director Centre for Bone Marrow Transplant
& Cellular Therapy
Indraprastha Apollo Hospital,
Delhi, India



Dr. Gaurav Kharya is the Clinical Lead of the Center for Bone Marrow Transplant and Cellular Therapy and serves as a Senior Consultant in Pediatric Hematology, Oncology, and Immunology. He graduated from Netaji Subash Chandra Bose Medical College, Jabalpur, and pursued a DCH in Pediatrics from Baba Raghav Das Medical College, Gorakhpur. After completing his DNB in Pediatrics at Sir Ganga Ram Hospital, Delhi, he served as a registrar and later specialized in Pediatric Hemato-Oncology and Bone Marrow Transplant (BMT).

Dr. Kharya played an instrumental role in establishing pediatric hemato-oncology services at Dr. B L Kapur Memorial Hospital, helping advance the BMT program. His expertise expanded further with international training at The Great North Children's Hospital, Newcastle, and St. Mary's Hospital, London, where he worked alongside prominent experts in pediatric hemato-oncology and BMT.

Returning to India in 2014, he joined BLK Super Specialty Hospital, where he focused on complex hematopoietic stem cell transplants, particularly alternative donor transplants. He is recognized for performing one of the largest numbers of BMTs for sickle cell disease (SCD) and has introduced innovative haploidentical transplant protocols in India. With over 1,000 transplants across various diseases, Dr. Kharya's team has completed more than 130 BMTs for SCD in recent years, including highly challenging cases, with successful outcomes.

In addition to his clinical work, Dr. Kharya is dedicated to research in cell and gene therapy, including CAR T cell therapy and gene manipulation for hemoglobin disorders. He is also committed to ensuring that financial constraints do not prevent children from receiving life-saving treatments, collaborating with NGOs to support families in need. His contributions have greatly impacted pediatric hemato-oncology and BMT, and his commitment to advancing accessible healthcare and pioneering research continues to shape the field.

POSTER PRESENTERS

- 1 **Sporadic Toxicities of CAR T-Cell Therapy: A brief write-up**
Dr. Bala Bhasker Poluru Mranikrinda, Specialist, Hamad Medical Corporation, Doha, Qatar
- 2 **Impact of Multimodal management of Invasive CNS fungal infection in a case of Pediatric Acute Myeloid Leukemia**
Dr. Ahmed Kamal Bayoumi, Senior Pediatric oncology and hematology specialist, National Cancer institute, Cairo university - Children's Cancer hospital Egypt 57357, Egypt
- 3 **Hepato-splenic candidiasis: an overlooked cause of prolonged fever in pediatric immunocompromised host**
Dr. Ahmed Kamal Bayoumi, Senior Pediatric oncology and hematology specialist, National Cancer institute, Cairo university - Children's cancer hospital 57357 , Egypt
- 4 **Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease in Childhood: Evaluation of Transplant-Related Toxicity and Survival Benefits**
Dr. Fatema Mohamed Alhashem, pediatric hematology fellow, KFSHRC-Riyadh, Riyadh -KSA
- 5 **Allogeneic Bone Marrow Transplantation For A Patient With Acquired Pure White Blood Cell Aplasia**
Dr. Mousa Ahmad Qatawneh, Pediatric Hemato-Oncology and BMT Senior Specialist, Queen Rania Al-Abdullah Children's Hospital, Amman- Jordan
- 6 **Hematopoietic Stem Cell Transplantation In Thalassemia Patients: A Jordanian Single Centre Experience**
Dr. Mousa Ahmad Qatawneh, Pediatric Hemato-Oncology and BMT Senior Specialist, Queen Rania Al-Abdullah Children's Hospital, Amman- Jordan
- 7 **Impact Of Donor Lymphocyte Infusion On Outcomes Of Myeloid Neoplasms Post Allogeneic Stem Cell Transplantation, Single Center Experience**
Dr. Asmaa Mohammed Elsheshtawy, pediatric oncology and malignant hematology, assistant consultant, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
- 8 **Cyclosporine A toxicity in pediatric allogeneic hematopoietic stem cell transplantation patients**
Dr. Mennatallah Shehab Elnaggar, BMT clinical pharmacist senior supervisor, Children Cancer Hospital Egypt 57357, Egypt
- 9 **Outcome of Hematopoietic Stem Cell Transplant in Beta-Thalassemia Major; Single Centre Experience from A low- and middle-income country**
Prof. Tariq Ghafoor, Pediatric Oncologist and Stem cell Transplant physician, Armed Forces Bone Marrow Transplant Centre Rawalpindi Pakistan, Rawalpindi, Pakistan
- 10 **Bleeding Phenotype of Glanzmann Thrombasthenia (GT) and Treatment Outcomes in over one hundred patients: A two-center experience in North Pakistan**
Dr. Muhammad Usman, Registrar Clinical Hematology, Armed Forces Bone Marrow Transplant Center, Combined Military Hospital Rawalpindi, Pakistan, Rawalpindi
- 11 **Posterior Reversible Encephalopathy Syndrome (PRES) After Allogeneic Stem Cell Transplantation in a Pediatric Patient with Beta Thalassemia**
Dr. Dilnoza Mirzayeva, child neurology, Center for the development of professional qualification of medical workers, Tashkent, Uzbekistan
- 12 **Treatment Outcome of Hematopoietic Stem Cell Transplant in Fanconi Anaemia; Experience from a low and middle-income country**
Dr. Hashim Khan, Resident Pediatric Clinical Hematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
- 13 **Clinical Analysis Of The Effectiveness of Haploidentical Allo-hsct In Patients With Acute Lymphoblastic Leukemia**
Dr. Rizaeva Feruza Abdulhamitovna, Hematologist, Scientific and practical medical center for children's oncology, hematology and immunology, Tashkent, Uzbekistan
- 14 **The use of ALLO-HSCT in children with acute leukemia**
Dr. Nargiza Babakhanova, Hematologist, Center of Pediatric Oncology, Hematology and Immunology, Tashkent, Uzbekistan
- 15 **Pediatric Transplant Data from a Center in a Remote Area in Interior Sindh, Pakistan**
Dr. Asghar Kerio, Senior Registrar, Gambat Institute of Medical Sciences, Gambat, Pakistan

POSTER PRESENTERS

- 16 Blinotumumab as a bridge therapy to bone marrow transplantation in refractory relapsed B-ALL. Case report.
Dr. Sapura Ibragimova, Ped/hematologist, Center of pediatric hematology, oncology and clinical immunology, Uzbekistan
- 17 Pattern of a Serum Biomarker Panel in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Single Center Study from Low/middle Income Country
Prof Dr. Ahmed Ibrahim Aly Elhemaly, Assistant professor of Paediatric oncology, National cancer institute, Cairo,Egypt
- 18 Successful Allogeneic Bone Marrow Transplant in a 3-Year-Old Child with DOCK8 Deficiency and disseminated disfiguring Molluscum Contagiosum: A success story from a resource limited country
Dr. Mussawair Hussain, Senior Registrar, Pakistan Kidney and Liver institute and Research center, Lahore, Pakistan
- 19 Hematopoietic stem cell transplantation in Infantile Osteopetrosis: Navigating through the maze
Dr. Hashim Khan, Resident, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
- 20 The experience with post-transplant cyclophosphamide as GVHD prophylaxis with peripheral blood stem cells allogeneic transplant in pediatrics
Dr. Ebtehal Mahmoud Abdelaziz Ali, Pediatric Oncology Assistant Lecturer, National Cancer Institute - Cairo University, Cairo, Egypt
- 21 Setting-up a Bone Marrow Transplant Unit in A Resource-Limited Country - Challenges and Learnings
Dr. Safia Khan, Consultant, Pediatric Hematology Oncology and BMT Physician, Pakistan Kidney and Liver Institution and Research Center, Lahore, Pakistan
- 22 Outcome of matched unrelated donors (MUD) stem cell transplant in Primary Immunodeficiencies Diseases (PIDs) at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia(2015-2019)
Dr. Salma Hussain Almohammed, Consultant of pediatric hematology oncology and stem cell transplantation, Oncology center, Alhassa
- 23 Second Hematopoietic Stem Cell Transplant For Graft Failure In A Very Severe Aplastic Anemia With Same Donor
Dr. Avinash Kumar Singh, consultant hematologist, Paras Hmri Hospital, Patna, Bihar, India
- 24 Autologous bone marrow transplantation in pediatric solid tumors without cryopreservation
Dr. Sayitov Begali Shokir Ugli, Pediatric Hematology and Oncology, National children's medical center, Uzbekistan
- 25 Patient-Parent Reported Quality of Life Assessment post Hematopoietic Stem Cell Transplant for Sickle Cell Disease: Validation and Clinical Application of Sickle Cell Disease Burden Index
Dr. Garima Nirmal, Consultant, Indraprastha Apollo Hospital, New Delhi, Delhi & India
- 26 Case series of Haploidentical Hematopoietic Stem Cell Transplant among Pediatric Homozygous Beta Thalassemia and Hemoglobinopathy E with interacting Beta Thalassemia patients in a tertiary hospital in the Philippines
Dr. Patricia Abigail B. Miranda, Pediatric Hematology Fellow / Physician, St. Luke's Medical Center - Quezon City, Philippines
- 27 "Impact Of Access To Global And Domestic Donor Pool For Patiens In India - Perspective of A Patient Registry"
Ms. Svenja Klett, Search Coordinator, DKMS Registry, Tübingen, Germany
- 28 Twenty-year outcome study on hematopoietic stem cell transplantation in childhood acute lymphoblastic leukemia: a single-center study from India
Dr. Anuraag Reddy Nalla, Fellow in paediatric BMT, Apollo Cancer Centres, Chennai, India
- 29 Pediatric Stem Cell Apheresis and Cryopreservation: Experience from a New Centre in Lower - Middle Income Country
Mr. Lokesh Chandershekhar, Assistant Social Welfare Officer, Kidwai Memorial Institute of Oncology, Bangalore, India
- 30 Comparison of Outcome of Good Risk versus High Risk Patients with Beta Thalassemia Major Undergoing Bone Marrow Transplantation in a Developing Country
Dr. Khalil Ur Rahman, Junior Consultant Clinical hematologist and bone marrow transplant physician, Pakistan Thalassemia Welfare society (PATHWEL) center of Hematoloy and Bone marrow Transplant, Rawalpindi, Pakistan

POSTER PRESENTERS

- 31 Twenty-year Outcome Study On Hematopoietic Stem Cell Transplantation In Childhood Acute Myeloid Leukemia: A Single-centre Study From India
Dr. Aarthi N, BMT Trainee, Apollo Cancer Institute, Teynampet- Chennai, Chennai
- 32 Pediatric HSCT in LMICs: A 15-Year Experience from The Children's Hospital, PIMS, Islamabad
Prof. Dr. Nuzhat Yasmeen, pediatric hem oncologist and BMT specialist, Children's hospital, Pakistan institute of medical sciences, Islamabad
- 33 Bortezomib As A Successful Second-line Therapy In Rituximab-refractory Autoimmune Hemolytic Anemia Post-stem Cell Transplant - A Case Report
Dr. Swapnil Tripathi, Senior resident(Academic), All India Institute of Medical Sciences, New Delhi, India
- 34 Intravesical Platelet Rich Plasma Application As Symptomatic Treatment of Bk Virus-associated Hemorrhagic Cystitis In Pediatric Patients After Hematopoietic Stem Cell Transplant
Dr. Aboubakar Yaya Mohamadou, General practitioner, Altinbas University Medicalpark Bahcelievler Hospital Pediatrics Hematology and Oncology, istanbul/turkiye
- 35 Post transplant cyclophosphamide as GvHD prophylaxis for peripheral blood stem cell in HLA related/ unrelated donor HSCT- A new paradigm shift
Dr. Garima Nirmal, Consultant Pediatric Hemato Oncologist and BMT Physician, Indraprastha Apollo Hospitals, New Delhi, India
- 36 Difficulties in treatment 4-year old boy with T-ALL after HSCT with hemorrhagic cystitis. Case Report Study.
Dr. Paweł Józefczuk, "Department of Oncology, Pediatric Hematology, Clinical Transplantology and Pediatrics University Clinical Center", Medical University of Warsaw, Poland
- 37 Hematopoietic stem cell transplant in Hemophagocytic Lymphohistiocytosis Disorders: single Center report on 28 patients
Dr. Stefano Rossi, Medical Doctor, Spedali Civili of Brescia, Brescia, Italy
- 38 Long Term Follow Up Of Pediatric Aplastic Anemia Patients Who Underwent Matched Sibling Donor Bone Marrow Transplantation - A Single Center Experience
Dr. Amiya Ranjan Nayak, Senior Resident, All India Institute of Medical Sciences, New Delhi, India
- 39 Post Hematopoietic Stem Cell Transplantation Care in a tertiary centre in the United Arab Emirates, opportunities and challenges
Dr. Fatimah H. Al-Taie, Pediatrics Resident, Tawam Hospital, AlAin-UAE
- 40 Successful Outcomes of Pediatric Haplo-identical HSCTs after Desensitization Treatment For Donor Specific Antibodies
Dr. Rasmi Palassery, Associate Professor, Ramaiah Medical College, Bengaluru, India
- 41 Improving Outcome Of Severe Aplastic Anemia In Pediatric Population By Increasing Access To Hematopoietic Stem Cell Transplantation - A Single Center Experience From Public Hospital In India
Dr. Anuj Singh, Assistant Professor, Post Graduate Institute of Child Health, Noida, India
- 42 Allogeneic Bone Marrow Transplantation Program For Sick Cell Disease In A Limited Resource Setting – Experience From Dodoma Central Tanzania
Dr. Shakilu Jumanne, Paediatric Haematology Oncologist, University of Dodoma, Dodoma, Tanzania
- 43 Assessment Of Adequacy Of Counselling Of Pediatric Stem Cell Donors
Dr. Santanu Sen, Senior Consultant & HOD, Pediatric Hematology, Oncology & BMT, Kokilaben Dhirubhai Ambani Hospital, Mumbai, india
- 44 Depression In Pediatric Stem Cell Donors
Serena Sen, A Level Student, Podar International School / Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
- 45 Incidence and Outcomes of Febrile Neutropenia in Pediatric Patients with Hematologic conditions: A Retrospective study
Dr. Ali Hussain Ansari, Research Associate at Children's Hospital Karachi, House Officer at Aga Khan University Hospital, Pakistan

[illegible]

SPONSORS & EXHIBITORS

PLATINUM SPONSOR



GOLD SPONSORS



EXHIBITORS



MEDIA PARTNER



ABOUT ABU DHABI

Abu Dhabi is the largest emirate in the United Arab Emirates, occupying 84 per cent of the national landmass territory. It has 200 islands and a long coastline stretching 700km. Its total area is 67,340 sq. km. Abu Dhabi city in the emirate is the federal capital of the UAE.

LOCATION AND GEOGRAPHY

The emirate of Abu Dhabi lies on the coast of the Arabian Gulf and is bordered by Sultanate of Oman to the east, the Kingdom of Saudi Arabia to the south and the west and the emirate of Dubai to the northeast. The three main regions of the emirate are:

- The city of Abu Dhabi
- Al Ain in the east
- Al Dhafrah (earlier known as Al Gharbia) in the west.

In the eastern region, to the south of Al Ain city is Jebel Hafeet - the emirate's highest peak (1,240 metres).

Al Dhafrah has seven main cities: Liwa, Madinat Zayed, Ghayathi, Ruwais, Mirfa, Sila and Delma Island.


The city of Abu Dhabi is connected to the mainland by four bridges: Maqta bridge, Mussafah bridge, Sheikh Zayed bridge and Sheikh Khalifa bridge.

TOURISTIC IMPORTANCE

Abu Dhabi has become a centre for world-class sporting events such as: the Abu Dhabi Golf Championship, the prestigious Abu Dhabi Desert Challenge cross-country rally and the Formula One Abu Dhabi Grand Prix.

In addition, the city will soon house the world's largest concentration of premier cultural institutions which will include the Sheikh Zayed National Museum, the Guggenheim Abu Dhabi and Louvre Abu Dhabi.

Abu Dhabi is rich in natural wonders too. While the emirate's famous Liwa oasis in the south of the emirate is home to some of the largest and most beautiful sand dunes in the world, the garden city of Al Ain in the foothills of Jebel Hafeet is home to several heritage sites.





Endorsed by

Paediatric Diseases
Working Party (PDWP)

Supported by

abu dhabi
Convention & Exhibition Bureau

3rd EMIRATES PEDIATRIC BONE MARROW TRANSPLANT & GENE THERAPY CONGRESS

9-10 November 2024 - Grand Hyatt Hotel, Abu Dhabi, UAE

“International get-together of Pediatric BMT physicians
to celebrate the success of saving children globally”



Organized by

شركة الشرق الأوسط وشمال أفريقيا للمؤتمرات ذ.م.م.

mena CONFERENCE

Middle East North Africa Conference Company LLC

www.menaconference.com